Skip to main content
NT

NanoVation Therapeutics™

NanoVation develops the SenseGuard, a nanosensor-based wearable device that enables non-invasive remote monitoring of critical respiratory parameters in patients with chronic respiratory diseases. This technology allows for early detection of respiratory deterioration, reducing unnecessary hospitalizations and associated healthcare costs.

Founded 20204710K+ followers
Updated 20 months ago

Funding

Funding not disclosed

CV
Funding rounds are not available yet.

Founders

Product

Problem

Patients with chronic respiratory diseases require frequent monitoring of respiratory parameters to detect deterioration early and prevent hospitalizations. Traditional methods often rely on clinic visits and forced expirations, which can be inconvenient, uncomfortable, and may not capture subtle changes in respiratory function. This can lead to delayed intervention and increased healthcare costs due to unnecessary hospital admissions.

Solution

NanoVation-GS offers SenseGuard, a wearable device utilizing nanosensor technology for non-invasive, remote monitoring of critical respiratory parameters. SenseGuard measures parameters derived from a patient's normal breathing, eliminating the need for forced expirations. The device enables early identification of respiratory deterioration, allowing healthcare professionals to intervene proactively and reduce unnecessary hospitalizations.

Target Audience

The primary target audience includes hospitals, insurers, home healthcare agencies, and patients with chronic respiratory conditions such as COPD and asthma.

Features

  • Nanosensor-based wearable device for non-invasive respiratory monitoring
  • Measures respiration rate, inhale/exhale ratio, duty cycle, and variability of respiratory parameters
  • Detects subtle changes in respiratory condition from tidal (normal) breathing
  • Designed for both home and hospital monitoring, suitable for self-measurement
  • Provides periodic evaluation of lung functions and detection of pending exacerbation
  • Lightweight and easy to use, suitable for elderly patients
This profile is AI-generated and may contain inaccuracies.